Table 2.

Bivalent HPV vaccine efficacy against incident CIN2+ by HPV types among women with at least 1 follow-up visit during each analytical period and no endpoint prior to each analytical period.

	Years 1-4						Years 7-11						Combined
	HPV Vaccine (N = 3467)		Control (N = 3492)		Vaccine Efficacy	Absolute Rate Difference	HPV Vaccine (N = 2767)		UCG (N = 2563)		Vaccine Efficacy	Absolute Rate Difference	HPV Vaccine	Control	Vaccine Efficacy	Absolute Rate Difference
HPV Type	#	Attack Rate (95% CI)	#	Attack Rate (95% CI)	% (95% CI)	Δ (95% CI)	#	Attack Rate (95% CI)	#	Attack Rate (95% CI)	% (95% CI)	Δ (95% CI)	Attack Rate (95% CI)	Attack Rate (95% CI)	% (95% CI)	Δ (95% CI)
Irrespective of HPV type	102	29·4 (24·2, 35·5)	153	43·8 (37·4, 51·0)	32·9% (13·8%, 47·8%)	−14·4 (−23·0, −5·4)	80	28·9 (23·1, 35·7)	109	42·5 (35·2, 50·9)	32·0% (9·3%, 49·2%)	−13·6 (−23·4, −3·5)	57·5 (49·3, 65·7)	84·5 (74·5, 94·5)	32·0% (18·1%, 43·7%)	−27·0 (−39·9, −14·2)
HPV 16/18	38	11·0 (7·9, 14·9)	83	23·8 (19·1, 29·2)	53·9% (32·6%, 68·9%)	−12·8 (−18·2, −6·8)	5	1·8 (0·7, 4·0)	47	18·3 (13·7, 24·1)	90·1% (76·8%, 96·5%)	−16·5 (−18·9, −12·5)	12·7 (8·9, 16·5)	41·3 (34·3, 48·4)	69·2% (57·3%, 78·9%)	−28·6 (−36·7, −20·6)
HPV 31/33/45 (excluding HPV 16/18 coinfection)	21	6·1 (3·9, 9·1)	27	7·7 (5·2, 11·1)	21·7% (−38·8%, 56·2%)	−1·7 (−5·4, 2·2)	14	5·1 (2·9, 8·3)	29	11·3 (7·7, 16·0)	55·3% (16·1%, 77·0%)	−6·3 (−10·4, −1·4)	11·0 (7·3, 14·6)	18·6 (13·7, 23·4)	40·9% (9·9%, 62·8%)	−7·6 (−13·9, −1·5)
Without HPV 16/18/31/33/45	43	12·4 (9·1, 16·5)	43	12·3 (9·0, 16·4)	−0·7% (−54·1%, 34·2%)	0·1 (−5·1, 5·3)	61	22·0 (17·1, 28·0)	33	12·9 (9·0, 17·8)	−71·2% (−164%, −12·5%)	9·2 (2·1, 15·6)	33·8 (27·4, 40·2)	24·6 (19·1, 30·2)	−37·3% (−86·0%, −2·7%)	9·2 (0·8, 17·8)

CI = confidence interval; CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; UCG = unvaccinated control group.

Rates are expressed as per 1,000 women.